VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

ALVAC-P53
Vaccine Information
  • Vaccine Name: ALVAC-P53
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Vaccine Ontology ID: VO_0004739
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Trp53 gene engineering:
    • Type: Recombinant vector construction
    • Description: Several canarypox virus recombinants expressing human or murine p53 in wild-type or mutant form were constructed (Roth et al., 1996).
    • Detailed Gene Information: Click Here.
  • Vector: canarypox vaccine vector
  • Preparation: Several canarypox virus recombinants expressing human or murine p53 in wild-type or mutant form were constructed (Roth et al., 1996).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Mice were immunized with the viruses constructed (Roth et al., 1996).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Mice were challenged with an isogenic and highly tumorigenic mouse fibroblast tumor cell line expressing high levels of mutant p53 (Roth et al., 1996).
  • Efficacy: The tumor protection was equally effective regardless of whether wild-type or mutant p53 was used for the immunization, indicating that the immunologic response was not dependent on any particular p53 mutation and that immunization with this live virus vaccine works effectively against mutant p53 protein expressed in a tumor cell (Roth et al., 1996).
References
Roth et al., 1996: Roth J, Dittmer D, Rea D, Tartaglia J, Paoletti E, Levine AJ. p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93(10); 4781-4786. [PubMed: 8643480].